# A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure

Study · id `cardio:ct-nct02681952` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02681952](<https://clinicaltrials.gov/study/NCT02681952>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02681952

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

## Technical summary

Registry record NCT02681952. Randomized; no masking; primary purpose other. Start 2015-12 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 153 participants (enrolled count; ClinicalTrials.gov record NCT02681952, source copy `cardio:ctgov-nct02681952-2017-07-06`, retrieved 2026-10-26)
- Start date: 2015-12 (registry gives no type) (ClinicalTrials.gov record NCT02681952, source copy `cardio:ctgov-nct02681952-2017-07-06`, retrieved 2026-10-26)
- Primary completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02681952, source copy `cardio:ctgov-nct02681952-2017-07-06`, retrieved 2026-10-26)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02681952, source copy `cardio:ctgov-nct02681952-2017-07-06`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02681952, source copy `cardio:ctgov-nct02681952-2017-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02681952-2017-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure
- Condition: Chronic Renal Failure
- Intervention (Drug): Renamezin capsule
- Intervention (Drug): Kremezin granule
- Lead sponsor: Daewon Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Daewon Pharmaceutical Co., Ltd. (`cardio:org-daewon-pharmaceutical-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial (`cardio:pubmed-33381933`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0cd3a2432b63f7d63c0e69e5ac74dde2f14a26ff63c17fce78025d61e9f9b9f6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
